SCHEMBL2652870

SCHEMBL2652870

CCc1cccc(NS(=O)(=O)c2ccccc2NC(=O)NC(c2ccc(C(=O)NCCC(=O)O)cc2)C2CCC(C3CCCCC3)CC2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCGR P47871 7/20 0.48
SMN1; SMN2 Q16637 3/20 0.39
MAPT P10636 3/20 0.39
ALDH1A1 P00352 2/20 0.39
ALOX12 P18054 1/20 0.39
GCG P01275 7/20 0.38
ADCY6 O43306 2/20 0.37
ADCY3 O60266 2/20 0.37
ADCY9 O60503 2/20 0.37
ADCY5 O95622 2/20 0.37
ADCY8 P40145 2/20 0.37
ADCY7 P51828 2/20 0.37
ADCY2 Q08462 2/20 0.37
ADCY1 Q08828 2/20 0.37
ADCY4 Q8NFM4 2/20 0.37
LMNA P02545 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
ACKR3 P25106 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2650549 0.92 MAPT (0.42) GCGRSMN1; SMN2MAPTALDH1A1ALOX12
SCHEMBL2650935 0.88 GCGR (0.53) GCGRSMN1; SMN2GCGACKR3GLP1R
SCHEMBL2661495 0.86 MAPT (0.42) GCGRSMN1; SMN2MAPTALDH1A1ALOX12
SCHEMBL2652873 0.86 ALDH1A1 (0.39) GCGRSMN1; SMN2MAPTALDH1A1ALOX12
SCHEMBL2650883 0.86 GCGR (0.49) GCGRSMN1; SMN2MAPTALDH1A1ALOX12
SCHEMBL2650553 0.84 ALDH1A1 (0.42) GCGRSMN1; SMN2MAPTALDH1A1ALOX12
SCHEMBL2652865 0.82 GCGR (0.58) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL2661497 0.81 ALDH1A1 (0.42) GCGRSMN1; SMN2MAPTALDH1A1ALOX12
SCHEMBL6748418 0.80 GCGR (0.48) GCGRSMN1; SMN2MAPTALDH1A1ADCY6
SCHEMBL2651127 0.79 L3MBTL1 (0.41) GCGRMAPTALDH1A1GCGMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040127560-A1 Glucagon antagonists/inverse agonists MADSEN PETER (DK) 2004-07-01 US claimed
US-6706744-B2 HYPOGLYCEMIC AGENTS; ANTIDIABETIC AGENTS NOVO NORDISK A/S (DK) 2004-03-16 US claimed
US-20030065031-A1 Glucagon antagonists/inverse agonists PFIZER INC 2003-04-03 US claimed
WO-2002040444-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2002-05-23 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040127560-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR GCGR 3/4885SMN1; SMN2 3651/4885MAPT 4386/4885
US-20030065031-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR GCGR 3/4885SMN1; SMN2 3651/4885MAPT 4386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.